SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-249487
Filing Date
2023-10-03
Accepted
2023-10-03 07:19:28
Documents
16
Period of Report
2023-10-03
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d556975d8k.htm   iXBRL 8-K 32662
2 EX-99.1 d556975dex991.htm EX-99.1 28537
6 GRAPHIC g556975g00a01.jpg GRAPHIC 8740
7 GRAPHIC g556975g1003023457499.jpg GRAPHIC 2995
8 GRAPHIC g556975g1003023457823.jpg GRAPHIC 5518
  Complete submission text file 0001193125-23-249487.txt   218476

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20231003.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20231003_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20231003_pre.xml EX-101.PRE 11259
10 EXTRACTED XBRL INSTANCE DOCUMENT d556975d8k_htm.xml XML 3353
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 231301550
SIC: 2835 In Vitro & In Vivo Diagnostic Substances